Clinical trials: Colorectal Cancer, Metastatic
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer Metastatic
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy.
- Trial name
- EPOCH (NCT01483027)
- Testing
- TheraSphere
- Where
- 131 sites in United States, Austria and 11 more
- Volunteers
- 428 people
- Sponsor
- Boston Scientific Corporation
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Colon Cancer
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
This is an exploratory biomarker study. Patients with metastatic colorectal cancer will receive regorafenib, which is FDA approved in this setting, on day 1-21 of every consecutive 28 day cycle.
- Trial name
- NCT02402036
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University
Metastatic Colorectal Cancer, Metastatic Breast Cancer
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer
This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer.
- Trial name
- BRECOL (NCT01733628)
- Where
- 10 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Spanish Breast Cancer Research Group
Colorectal Neoplasms
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated…
- Trial name
- NCT00609622
- Testing
- sunitinib, mFOLFOX6, bevacizumab
- Where
- 97 sites in United States, Denmark and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Metastatic Colorectal Cancer
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to…
- Trial name
- NCT02448810
- Testing
- BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV
- Where
- 12 sites in United States
- Volunteers
- 115 people
- Sponsor
- Baxalta now part of Shire
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
The investigators are investigating the use of a new cancer treatment called Irreversible Electroporation (IRE). This treatment delivers electrical energy between two needles placed in a cancer.
- Trial name
- NCT02461550
- Testing
- Irreversible Electroporation Ablation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasms, Metastases
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
This is a phase II, multicenter, open-label study of cetuximab in patients with epidermal growth factor receptor (EGFR) negative, metastatic colorectal carcinoma who have progressed after receiving at least one standard…
- Conditions
- Colorectal Neoplasms, Metastases, Neoplasm
- Trial name
- NCT00083720
- Testing
- cetuximab
- Where
- 27 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Colon Cancer, Recurrent Rectal Cancer
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
This phase II trial is studying how well VEGF Trap works in treating patients with previously treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by blocking blood flow to the tumor.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00407654
- Testing
- aflibercept
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416494
- Testing
- bevacizumab, oxaliplatin, Capecitabine
- Volunteers
- 50 people
- Sponsor
- Herbert Hurwitz, MD
Colorectal Cancer
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in…
- Trial name
- CanStem303C (NCT02753127)
- Testing
- Napabucasin, Fluorouracil, Leucovorin
- Where
- 211 sites in United States, Australia and 14 more
- Volunteers
- 1,253 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Cancer
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Although treatment for metastatic colorectal cancer has improved significantly over the recent years, it still remains a significant health problem representing the leading cancer by incidence in the United States of America.
- Trial name
- NCT00199797
- Testing
- Oxaliplatin, 5-Fluorouracil, Leucovorin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Ludwig Institute for Cancer Research
Recurrent Colon Cancer, Recurrent Rectal Cancer
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
This phase II trial is studying how well giving azacitidine together with entinostat works in treating patients with metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01105377
- Testing
- entinostat, azacitidine, laboratory biomarker analysis
- Where
- 14 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)